Physician profile
Charles Patrick Cole
NPI 1316021751
$5,505.74
in general payments reported to CMS, 2019-2025
36 companies · $896 in 2025
The $896 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $660 · 2020: $711 · 2021: $541 · 2022: $1,021 · 2023: $878 · 2024: $797 · 2025: $896.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,572.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,571.73 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $679.99 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $600.51 | 2019-2025 | Mounjaro, Emgality, Zepbound |
| Abbvie INC. | $488.38 | 2020-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $477.52 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $427.97 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $314.26 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Takeda Pharmaceuticals U.S.A., INC. | $302.67 | 2019-2025 | Trintellix, Gattex |
| Janssen Pharmaceuticals, INC | $295.05 | 2019-2023 | Xarelto |
| Boehringer Ingelheim Pharmaceuticals, INC. | $190.58 | 2020-2025 | Jardiance, Synjardy |
| Lundbeck LLC | $177.17 | 2022-2025 | Rexulti |
| Glaxosmithkline, LLC. | $172.17 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $140.69 | 2020-2025 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $140.64 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $105.46 | 2019-2023 | Verquvo, Belsomra, Steglatro |
| Otsuka America Pharmaceutical, INC. | $102.38 | 2025 | Rexulti |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Atricure, INC. | $101.86 | 2024 | |
| Haemonetics Corporation | $94.65 | 2022 | |
| Novartis Pharmaceuticals Corporation | $87.51 | 2024-2025 | |
| Exact Sciences Corporation | $83.85 | 2023-2024 | Cologuard Collection Kit |
| Amarin Pharma, INC. | $62.19 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $59.56 | 2022 | |
| Phathom Pharmaceuticals, INC. | $47.53 | 2024-2025 | Voquezna |
| Allergan, INC. | $43.24 | 2019-2020 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.73 | 2025 | Caplyta |
| Eisai INC. | $38.02 | 2021 | |
| Daiichi Sankyo INC. | $34.25 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $34.10 | 2022 | |
| Currax Pharmaceuticals LLC | $30.08 | 2022 | |
| Esperion Therapeutics, INC. | $26.55 | 2020 | |
| Paratek Pharmaceuticals, INC. | $17.25 | 2024 | Nuzyra |
| Shire North American Group INC | $17.22 | 2019 | |
| Seqirus USA INC | $15.34 | 2022 | |
| Aimmune Therapeutics, INC. | $15.07 | 2025 | Zenpep |
| Boston Scientific Corporation | $14.43 | 2022 | |
| Phadia US INC. | $13.69 | 2024 | Immunocap |
| Sanofi-Aventis U.S. LLC | $12.18 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charles Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.